Clinical Trials
56 trialsPh. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
PIKALO-1
Eli Lilly and Company
TRIDENT-1
Turning Point Therapeutics, Inc.
OP-NEU-101
Onchilles Pharma Inc
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
LIBRETTO-001
Eli Lilly and Company
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
EMITT-1
Grey Wolf Therapeutics
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
LIBRETTO-121
Eli Lilly and Company
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
FORCE
University of Kansas Medical Center
DENALI-1
A2 Biotherapeutics Inc.
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
START-001
Marengo Therapeutics, Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
ARROW
Hoffmann-La Roche
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
ENHANCE
Xynomic Pharmaceuticals, Inc.
IT-01
Intensity Therapeutics, Inc.
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
NKGen Biotech, Inc.
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
CytomX Therapeutics
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
CytomX Therapeutics
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Advaxis, Inc.
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune LLC
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Eisai Inc.
INSIGHT-2
Royal Marsden NHS Foundation Trust
A Study of AK-01 (LY3295668) in Solid Tumors
Eli Lilly and Company
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Effector Therapeutics
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Tactile Medical
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Institutes of Health Clinical Center (CC)